Venus Remedies Limited (VENUSREM.BO)
INR 325.25
(-0.15%)
INR 325.25
(-0.15%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 413.3 Million INR | -2.28% |
| 2022 | 422.93 Million INR | -1.29% |
| 2021 | 428.45 Million INR | -16.51% |
| 2020 | 513.18 Million INR | -76.72% |
| 2019 | 2.2 Billion INR | -26.02% |
| 2018 | 2.97 Billion INR | -2.9% |
| 2017 | 3.06 Billion INR | -1.52% |
| 2016 | 3.11 Billion INR | -7.04% |
| 2015 | 3.35 Billion INR | 4.5% |
| 2014 | 3.2 Billion INR | 11.13% |
| 2013 | 2.88 Billion INR | 6.41% |
| 2012 | 2.71 Billion INR | 23.13% |
| 2011 | 2.2 Billion INR | 150.39% |
| 2010 | 879.84 Million INR | -41.1% |
| 2009 | 1.49 Billion INR | 13.52% |
| 2008 | 1.31 Billion INR | 37.48% |
| 2007 | 957.17 Million INR | 12.54% |
| 2006 | 850.48 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 409.1 Million INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 417.4 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 413.3 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 413.3 Million INR | -2.28% |
| 2022 Q2 | 422.8 Million INR | 0.0% |
| 2022 FY | 422.93 Million INR | -1.29% |
| 2022 Q4 | 422.93 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 428.45 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 429.86 Million INR | 0.0% |
| 2021 FY | 428.45 Million INR | -16.51% |
| 2020 FY | 513.18 Million INR | -76.72% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 666.3 Million INR | 0.0% |
| 2020 Q4 | 513.18 Million INR | 0.0% |
| 2019 Q4 | 2.2 Billion INR | 0.0% |
| 2019 FY | 2.2 Billion INR | -26.02% |
| 2019 Q2 | 1.87 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 2.97 Billion INR | -2.9% |
| 2018 Q4 | 2.97 Billion INR | 0.0% |
| 2017 FY | 3.06 Billion INR | -1.52% |
| 2016 FY | 3.11 Billion INR | -7.04% |
| 2016 Q4 | 2.8 Billion INR | 0.0% |
| 2015 FY | 3.35 Billion INR | 4.5% |
| 2014 FY | 3.2 Billion INR | 11.13% |
| 2013 Q4 | 2.88 Billion INR | 0.0% |
| 2013 FY | 2.88 Billion INR | 6.41% |
| 2012 Q4 | 2.71 Billion INR | 0.0% |
| 2012 Q2 | 238.98 Million INR | 0.0% |
| 2012 FY | 2.71 Billion INR | 23.13% |
| 2011 FY | 2.2 Billion INR | 150.39% |
| 2010 FY | 879.84 Million INR | -41.1% |
| 2009 FY | 1.49 Billion INR | 13.52% |
| 2008 FY | 1.31 Billion INR | 37.48% |
| 2007 FY | 957.17 Million INR | 12.54% |
| 2006 FY | 850.48 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -17.149% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -2291.367% |
| Sigachi Industries Limited | 1.43 Billion INR | 71.108% |
| Bal Pharma Limited | 1.39 Billion INR | 70.404% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -148.652% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Medico Remedies Limited | 80.5 Million INR | -413.391% |
| Lasa Supergenerics Limited | 220.76 Million INR | -87.215% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 32.412% |
| Alpa Laboratories Limited | 52.46 Million INR | -687.763% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 93.497% |
| NATCO Pharma Limited | 3.71 Billion INR | 88.866% |
| Shilpa Medicare Limited | 9.37 Billion INR | 95.591% |
| Aarti Drugs Limited | 5.64 Billion INR | 92.675% |
| Lupin Limited | 29.21 Billion INR | 98.585% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.378% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 94.861% |
| Windlas Biotech Limited | 36.41 Million INR | -1035.128% |
| Suven Life Sciences Limited | 7.09 Million INR | -5723.587% |
| Eris Lifesciences Limited | 27.81 Billion INR | 98.514% |
| Valiant Laboratories Limited | 767.08 Million INR | 46.121% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 89.056% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 95.914% |
| Ipca Laboratories Limited | 14.38 Billion INR | 97.127% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 42.983% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 58.604% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 98.738% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 87.582% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 80.05% |
| Laurus Labs Limited | 25.77 Billion INR | 98.396% |
| Piramal Pharma Limited | 47.1 Billion INR | 99.123% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -141.019% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 98.972% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 91.946% |
| Medicamen Biotech Limited | 308.17 Million INR | -34.113% |
| Gufic Biosciences Limited | 3.32 Billion INR | 87.585% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 96.642% |
| Unichem Laboratories Limited | 2.47 Billion INR | 83.302% |
| Sequent Scientific Limited | 4.87 Billion INR | 91.525% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -26.16% |
| Ind-Swift Limited | 10.13 Billion INR | 95.924% |
| Novartis India Limited | 69.7 Million INR | -492.97% |
| Wanbury Limited | 1.16 Billion INR | 64.519% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 36.412% |
| Wockhardt Limited | 23.56 Billion INR | 98.246% |
| Themis Medicare Limited | 957.92 Million INR | 56.855% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -362.253% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 98.872% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 97.936% |
| Divi's Laboratories Limited | 30 Million INR | -1277.667% |
| FDC Limited | 205.18 Million INR | -101.428% |
| Procter & Gamble Health Limited | 95.6 Million INR | -332.322% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 78.633% |
| Granules India Limited | 13.15 Billion INR | 96.857% |
| Alkem Laboratories Limited | 14.18 Billion INR | 97.086% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -798.83% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -9316.724% |
| Brooks Laboratories Limited | 56.41 Million INR | -632.555% |
| Megasoft Limited | 1.47 Billion INR | 71.893% |
| ZIM Laboratories Limited | 1.08 Billion INR | 62.021% |
| Strides Pharma Science Limited | 25.16 Billion INR | 98.358% |
| Neuland Laboratories Limited | 953.89 Million INR | 56.672% |
| Morepen Laboratories Limited | 289.99 Million INR | -42.521% |
| Hikal Limited | 8.17 Billion INR | 94.945% |
| Indoco Remedies Limited | 6.71 Billion INR | 93.849% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 85.511% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -30.599% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 58.037% |
| Hester Biosciences Limited | 2.44 Billion INR | 83.088% |